Subsidiary of MammoRisk by Predilife for €202 million

Predilife, a specialist in medical risk prediction solutions, has finalized the partial contribution of assets of its MammoRisk branch, valued at €202 million. The objective of this transaction, concluded on November 7, 2024, is to enable MammoRisk to develop independently and extend its influence internationally.

MammoRisk, already well established in the field of breast cancer screening, is targeting a potential market of 100 million European women over 40. This strategic positioning should facilitate the creation of partnerships and accelerate its global deployment.

By transferring this branch to its dedicated subsidiary, Predilife hopes to diversify its sources of financing and offer better valuation to its shareholders. This operation was validated by Sorgem Evaluation and the firm Grant Thornton France.